Wereport a patient with an initial relapse of acute promyelocytic leukemia (APL) who achieved a second complete remission (CR) after treatment with arsenic trioxide. The patient, a 66-year-old womandiagnosed as having relapsed APL, received arsenic trioxide intravenously at a dose of 10 mg/day. At day 36, the patient achieved a second CR.
Introduction
All trans retinoic acid (ATRA), proven to be effective for de novo acute promyelocytic leukemia (APL), has been shown to induce a 90%complete remission (CR) rate and result in a 60%long-term survival rate. However, relapse occurs in about 30%of patents after the initial CR (1) . For relapsed patients, it is difficult to obtain a second CR with ATRAalone or in combination with chemotherapy (1, 2) . In 1997, arsenic trioxide was introduced for treatment of patients with relapsed APL (3, 4) and its remarkable effectiveness was confirmed in subsequent studies (5, 6) . However, reports on the use of arsenic trioxide in Japan are rare (7) . Here, we describe a patient with APLwhoachieved a second CR following treatment with arsenic trioxide, with only mild side effects.
Case Report A66-year-old womanwas admitted to our hospital because of relapsed APLin June 2000. She had a history ofAPL from 1993 and had obtained the first CR with administration ofATRA alone followed by 5 courses of consolidation chemotherapy. She was followed up as an outpatient from September 1995. Laboratory data on admission showed mild anemia (red blood cell count 2.54xlO12//) with decreased white blood cell count (1.9x107/) and a platelet count (120x107/). Disseminated intravascular coagulation was not present. The marrow smears showed increased promyelocytes (26%) and decreased neutrophils (4%). The karyotype of the bone marrow cells showed t (15: 17) in 25% of the cells. The proportion ofpromyelocyte leukemia-retinoic acid receptor al fa (PML-RARA) fusion transcript by fluorescent in situ hybridization (FISH) was 32%.
Werecommended the patient to consider treatment with Am80 (8, 9) , however the patient refused this therapy since there was no institution near our hospital capable of performing this treatment. Next, we considered administration of arsenic trioxide. Weinvestigated the possibility of importing this drug from United States or China, but that proved to be impossible, so we considered to use research arsenic agent. The successful use of this research reagent had been reported in Japan in 2000 (7), supported our decision. The institutional review board of our hospital approved this arsenic therapy for this patient. Weexplained to the patient the optional strategy of first administering ATRAand chemotherapy and only resorting to arsenic trioxide if this initial therapy failed. However, the patient rejected this idea because the low possibility of a second CRby combination therapy, and instead opted for the treatment first by arsenic trioxide. Wealso explained the pos- Reprint requests should be addressed to Dr. Yasuo Hirayama, the Department of Internal Medicine, Higashi Sapporo Hospital, 3-3 Shiro-ishi-ku, Sapporo 003-of IN NaOHwas added to the mixture. The pH was adjusted by the addition of 10 ml of IN HC1 and the final volume was adjusted to 200 ml.The final solution (0.1% solution) was tranferred to a 10 ml vial and autoclaved. Before administration, one vial of the solution was added to 500 ml normal saline solution. The administration of ten milligrams/day of arsenic trioxide as described by Chen et al (3) was started on June 21, 2000 (Fig. 1) . The percentage of bone marrow promyelocyte started to decrease on day 28. At this time, myelocyte-like cells, without azur granules and nucleic bodies, began to increase (Fig. 2) . The proportion of promyelocytes reached 2%at day 36 and the administration was stopped. At this time the percentage of PML-RARA positive cells by FISH was 20%, thus positive cells morphologically lacking promyelocytes were thought to exist. At this time, fusion signal appeared in the cells with lobed nuclei, indicating the differentiation of APL cells by arsenic trioxide (Fig. 3) . At day 54 FISH positive cells had decreased to 2%.
Lower abdominal skin erythematous changes appeared 10 days after the start of arsenic trioxide treatment, (Fig. 4) , however, they diminished once administration of the drug was stopped. Mild neuralgia occurred after the arsenic administration and improved one week after treatment ended. Long-term toxicity has not been observed. After hematological recovery, idarbicin and Ara C were administered as consolidation therapy. PML-RARAmRNAwas undetectable by reverse transcription polymerase chain reaction in the bone marrowcells after the first consolidation chemotherapy.
Discussion
Relapsed APLshows resistance to ATRA because of increased levels of cellular retinoic acid binding protein (CRABP), mutations in the retinoic acid receptor gene and additional genetic abnormalities. Recently, two new promising agents, Am80 and arsenic trioxide, have been introduced for treatment of relapsed APL. The remarkable effect of arsenic trioxide for APLwas first reported in 1997 by a Chinese group (3, 4) and it was reconfirmed by a study in the U.S. in 1998 (5). The two-year survival rate after arsenic therapy was reported to be 40%which is excellent in comparison with the combination ofATRAand chemotherapy for relapsed APL(6).
Previously reported side effects were skin eruption, liver dysfunction, nausea, vomiting, retinoic acid syndrome, cardiac dysfunction and pleural effusion. Fortunately, the present patient suffered only mild skin erythematous change and neuralgia, which resolved after cessation of arsenic trioxide (10, 1 1 was reported to be as muchas 80%, whereas the consolidation chemotherapygroup after arsenic showeda relapse rate of only 30% (6), indicating, obviously, the benefit of the latter treatment following successful second CR. Moreover, a new synthetic retinoid, Am80 (4-[(5, 6, 7, 8-tetrahydro-5, 5, 8, 8-teramethyl-2-naphtalenyl) carbamoil] benxoic acid), has also been proven to produce beneficial effect in patients with relapsed APL (8, 9) . The adverse effects ofAm80 are milder than those of arsenic. In the future, Am80maybecome the drug of choice, instead of arsenic, to treat relapsed APL, because the side effects are less severe.
Although arsenic therapy can be highly beneficial to patients with APL,a cautious approach to its use should be adopted because of several possible adverse effects.
